McKesson Corporation has been a trending topic in the market lately, attracting considerable investor attention. Despite recent market gains, McKesson's stock took a slight dip, being cut to Neutral due to an “unusual” sell side event. There are warnings of 'wall of worry' building in advance of a November update. Nevertheless, the corporation announced its second-quarter fiscal 2025 earnings release date illustrating the firm's forward planning. Notably, Susquehanna Fundamental Investments invested $6.40 Million in McKesson, displaying institutional interest. The corporation's institutional investors experienced volatility with 11% lost last week, but they have benefitted from longer-term gains. Over the last five years, its investors have seen a significant return of 286%. The company also showed signs of potential long-term value. Yet, a recent downgrade by Baird and a stock price target cut by Deutsche Bank weigh on this trend. Still, McKesson has demonstrated fiscal resilience with a first quarter earnings beat, despite a revenue miss due to the U.S. pharmaceutical segment. Another worthy mention would be the sale of its Rexall and Well.ca businesses to Birch Hill Equity Partners. Despite some shortcomings, the earning guidance surpassed expectations and has recently raised its quarterly dividend by 15%.
Mckesson Corporation MCK News Analytics from Wed, 07 Feb 2024 08:00:00 GMT to Sun, 29 Sep 2024 09:00:41 GMT -
Rating 3
- Innovation 7
- Information 7
- Rumor 0
